Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Prothena Corp (PRTA)

Prothena Corp (PRTA)
10.22 +0.53 (+5.47%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 10.00 -0.22 (-2.13%) 04/11/25
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
9.59
Day High
10.27
Open 9.69
Previous Close 9.69 9.69
Volume 443,700 443,700
Avg Vol 578,140 578,140
Stochastic %K 17.47% 17.47%
Weighted Alpha -59.09 -59.09
5-Day Change -0.64 (-5.89%) -0.64 (-5.89%)
52-Week Range 9.30 - 25.42 9.30 - 25.42
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 550,112
  • Shares Outstanding, K 53,827
  • Annual Sales, $ 135,160 K
  • Annual Income, $ -122,310 K
  • EBIT $ -155 M
  • EBITDA $ -151 M
  • 60-Month Beta 0.07
  • Price/Sales 3.86
  • Price/Cash Flow N/A
  • Price/Book 1.07

Options Overview Details

View History
  • Implied Volatility 120.31% ( -1.11%)
  • Historical Volatility 62.28%
  • IV Percentile 85%
  • IV Rank 33.23%
  • IV High 262.36% on 11/19/24
  • IV Low 49.62% on 06/25/24
  • Put/Call Vol Ratio 3.57
  • Today's Volume 32
  • Volume Avg (30-Day) 218
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 7,517
  • Open Int (30-Day) 5,693

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.92
  • Number of Estimates 5
  • High Estimate -0.57
  • Low Estimate -1.10
  • Prior Year -1.34
  • Growth Rate Est. (year over year) +31.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.30 +9.89%
on 04/09/25
Period Open: 13.75
14.34 -28.73%
on 03/14/25
-3.53 (-25.67%)
since 03/11/25
3-Month
9.30 +9.89%
on 04/09/25
Period Open: 13.05
16.67 -38.67%
on 02/21/25
-2.83 (-21.69%)
since 01/10/25
52-Week
9.30 +9.89%
on 04/09/25
Period Open: 23.28
25.42 -59.80%
on 07/25/24
-13.06 (-56.10%)
since 04/11/24

Most Recent Stories

More News
Prothena: Q4 Earnings Snapshot

Prothena: Q4 Earnings Snapshot

PRTA : 10.22 (+5.47%)
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study

Roche RHHBY announced data from the phase IIb PADOVA study which evaluated its investigational monoclonal antibody, prasinezumab, for treating people with early-stage Parkinson’s disease.The double-blind...

CSTL : 19.70 (+2.07%)
PRTA : 10.22 (+5.47%)
RHHBY : 38.1000 (+3.36%)
SPRO : 0.6000 (+3.90%)
Prothena: Q3 Earnings Snapshot

Prothena: Q3 Earnings Snapshot

PRTA : 10.22 (+5.47%)
Prothena: Q2 Earnings Snapshot

Prothena: Q2 Earnings Snapshot

PRTA : 10.22 (+5.47%)
Prothena Reports First Quarter 2023 Financial Results and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial...

PRTA : 10.22 (+5.47%)
Prothena to Report First Quarter 2023 Financial Results on May 4

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 10.22 (+5.47%)
Prothena to Participate in 2023 Bank of America Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 10.22 (+5.47%)
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety...

PRTA : 10.22 (+5.47%)
WBA : 10.78 (+0.84%)
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new...

PRTA : 10.22 (+5.47%)
Prothena to Participate in Stifel 2023 Virtual CNS Days

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 10.22 (+5.47%)

Business Summary

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis...

See More

Key Turning Points

3rd Resistance Point 11.15
2nd Resistance Point 10.71
1st Resistance Point 10.47
Last Price 10.22
1st Support Level 9.78
2nd Support Level 9.34
3rd Support Level 9.09

See More

52-Week High 25.42
Fibonacci 61.8% 19.26
Fibonacci 50% 17.36
Fibonacci 38.2% 15.46
Last Price 10.22
52-Week Low 9.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar